인터류킨 17(IL-17) 억제제 시장 - 표적 집단, 경쟁 구도, 시장 예측(2034년)

Key Highlights:

• Interleukin-17 (IL-17) inhibitors are a group of targeted biologic therapies designed to block specific interleukins cytokines that play key roles in regulating the immune system and driving inflammation. These inhibitors are commonly used in the treatment of autoimmune and inflammatory diseases such as psoriasis, plaque psoriasis ankylosing spondylitis, rheumatoid arthritis, and asthma.
• Currently, several IL-17 inhibitors approved, including BIMZELX (bimekizumab), SILIQ (brodalumab), TALTZ (ixekizumab), COSENTYX (secukinumab) and others.
• Market growth is further fueled by increasing prevalence of autoimmune diseases, greater physician awareness, and broader access to biologic therapies.
• BIMZELX's dual inhibition of both IL-17A and IL-17F offers a more comprehensive suppression of inflammation, which clinical studies suggest may result in faster and more robust responses than single-cytokine inhibitors. This scientific differentiation is a key competitive advantage, as IL-17F is now recognized as an important driver in diseases like psoriasis and hidradenitis suppurativa.
• Response rates to IL-17 inhibitors are higher in biologic-naive patients. Those with prior biologic exposure, particularly to TNF inhibitors, often have more refractory disease and may require alternative or combination approaches.
• The emerging drug pipeline for IL-17 Inhibitor is diverse and includes several promising candidates, such as Sonelokimab (MoonLake Immunotherapeutics), Izokibep (Affibody Medical AB), SFA-002 (SFA Therapeutics), Simepdekinra (DICE Therapeutics/Eli Lilly) and others.
• Among novel IL-17 inhibitors, Izokibep is one of the most advanced, currently in Phase III trials for ankylosing spondylitis and psoriatic arthritis, with additional development in hidradenitis suppurativa. Its unique affibody design offers high potency and deep tissue penetration, aiming to improve outcomes over first-generation IL-17 inhibitors.
• In April 2025, Affibody Medical AB reported positive Phase II clinical results for izokibep in psoriatic arthritis, highlighting its potent IL-17A inhibition and clinical improvements in joint and skin symptoms.
• The entry of newer IL-17 inhibitors intensifies competition among existing drugs, likely leading to pricing pressures, and more aggressive payer contracting to maintain or gain formulary positioning.

DelveInsight's "IL-17 Inhibitors- Target Population, Competitive Landscape, and Market Forecast-2034" report delivers an in-depth understanding of the IL-17, historical and Competitive Landscape as well as the IL-17 inhibitor market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The IL-17 inhibitors market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM IL-17 inhibitors market size from 2020 to 2034. The report also covers current IL-17 treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Interleukin-17 (IL-17) Inhibitors Understanding

Interleukin-17 (IL-17) Overview

Interleukin-17 (IL-17) inhibitors are a class of monoclonal antibodies that target IL-17A or its receptor, a key cytokine involved in driving inflammation in several autoimmune and inflammatory diseases. These therapies work by blocking IL-17A directly or inhibiting its receptor (IL-17RA), which prevents the activation of downstream signaling pathways responsible for recruiting immune cells and amplifying the inflammatory response. IL-17 inhibitors are primarily used in the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis. By disrupting the IL-17 signaling pathway, these agents help suppress chronic inflammation, reduce tissue damage, and improve disease symptoms. Currently approved IL-17 inhibitors include COSENTYX, TALTZ, SILIQ, BIMZELX and Others.

IL-17 Inhibitors Epidemiology

The IL-17 inhibitors epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total cases of selected indication for IL-17 inhibitor, total eligible patient pool for IL-17 inhibitor in selected indication, and total treated cases in selected indication for IL-17 inhibitors in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• The total diagnosed prevalent cases of myotonic dystrophy in the 7MM were ~15 million in 2024.
• Psoriasis is predominantly observed in adults, accounting for maximum cases in the 7MM.
• In 2024, among the type-specific cases of psoriasis, erythrodermic psoriasis accounted for the least number of cases in the 7MM.
• In EU4 and the UK, plaque psoriasis cases were maximum in Germany with ~1.6 million in 2024.
• Japan accounted for ~500 prevalent Psoriasis cases in 2024.

IL-17 Drug Chapters

The drug chapter segment of the IL-17 inhibitor reports encloses a detailed analysis of late-stage (Phase III and Phase II) pipeline drugs. It also helps understand the IL-17 inhibitor's clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Marketed IL-17 Inhibitors

BIMZELX (bimekizumab): UCB Pharma

BIMZELX is a humanized immunoglobulin IgG1/? monoclonal antibody with two identical antigen-binding regions that selectively bind to human interleukin 17A (IL-17A), interleukin 17F (IL-17F), and interleukin 17-AF cytokines, and inhibits their interaction with the IL-17 receptor complex. In October 2024, the FDA approved BIMZELX at a 320 mg dose for adults with moderate-to-severe plaque psoriasis and for those with psoriatic arthritis with coexistent skin involvement. Indications, psoriatic arthritis without skin symptoms, non-radiographic axial spondyloarthritis and ankylosing spondylitis- a 160 mg dose is recommended.

SILIQ/KYNTHEUM/LUMICEF (brodalumab): AstraZeneca/Bausch Health/Kyowa Kirin/LEO Pharma

SILIQ is a human IL-17 Receptor A (IL-17RA) antagonist indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. In the US is named "SILIQ"; in Europe, it is named "KYNTHEUM," and in Japan, it is called "LUMICEF".

In July 2017, AstraZeneca and MedImmune announced that its partner LEO Pharma has been granted full marketing authorization in all 28 EU member countries for KYNTHEUM for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.

In February 2017, the US FDA approved SILIQ to treat adults with moderate-to-severe plaque psoriasis. SILIQ is administered as an injection.

In May 2015, Amgen ended its agreement with AstraZeneca to develop a new biologic for psoriasis because of the likelihood of 'restrictive labeling' due to the drug's potential risk of suicidal thoughts.

Emerging IL-17 Inhibitors

Sonelokimab: MoonLake Immunotherapeutics

Sonelokimab is a next-generation biologic drug developed by MoonLake Immunotherapeutics that targets both interleukin-17A and interleukin-17F using a nanobody-based format. Sonelokimab is currently in late-stage clinical development for several immune-mediated inflammatory disorders. It has shown promising results in moderate-to-severe hidradenitis suppurativa (HS), where it is being evaluated in Phase III trials (MIRA study). In psoriatic arthritis and axial spondyloarthritis (axSpA), Phase II data has demonstrated strong joint and skin responses, highlighting its potential in rheumatologic conditions.

In January 2025, MoonLake Immunotherapeutics announced the initiation of three new clinical trials for its Nanobody candidate, sonelokimab, further expanding its development program across dermatologic and rheumatologic conditions. The trials include VELA-TEEN, a Phase III study in adolescent patients with hidradenitis suppurativa (HS), LEDA, a Phase II trial in patients with palmoplantar pustulosis (PPP) and S-OLARIS, a Phase II trial in axial spondyloarthritis (axSpA).

Izokibep: Affibody Medical AB

Izokibep is a small-format IL-17A inhibitor designed for high potency and deep tissue penetration. Developed by Affibody and ACELYRIN, it has shown strong efficacy in treating inflammatory diseases like hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis. Its compact design offers subcutaneous delivery with potentially fewer injections and improved tissue targeting compared to traditional biologics. Izokibep is being investigated in Phase III trials for ankylosing spondylitis (AS) and psoriatic arthritis (PsA), where it has demonstrated strong early efficacy signals and a favorable safety profile.

In February 2025, Affibody regained worldwide rights to izokibep. In 2021, Affibody and ACELYRIN, INC. entered into a license and collaboration agreement granting ACELYRIN worldwide development and commercialization rights to izokibep, except in selected Asian countries.

IL-17 Inhibitor Market Outlook

The IL-17 inhibitor class has established itself as a pivotal therapeutic option in the management of chronic immune-mediated inflammatory diseases, particularly Psoriasis, plaque psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (AS). These agents work by directly targeting IL-17A, IL-17F, or the IL-17 receptor, cytokines that are central to the pro-inflammatory activity of Th17 cells. Since the approval of secukinumab (Cosentyx) by Novartis in 2015-the first IL-17 inhibitor to enter the market-the class has seen steady growth, driven by robust clinical efficacy, rapid onset of action, and expanding indications across dermatology and rheumatology. The IL-17 inhibitor market is currently dominated by COSENTYX (secukinumab), followed by TALTZ (ixekizumab) from Eli Lilly, and SILIQ (brodalumab) from Amgen/Kyowa Kirin. More recently, BIMZELX (bimekizumab) from UCB has emerged as a dual IL-17A/IL-17F inhibitor with approvals in Europe and the US.

As the market matures, innovation is shifting toward next-generation IL-17 inhibitors with enhanced tissue penetration, higher affinity, and extended dosing intervals. Two promising candidates are sonelokimab (MoonLake Immunotherapeutics), a trivalent nanobody targeting IL-17A and IL-17F, and izokibep (Affibody/Inmagene Bio), an engineered affibody molecule that binds IL-17A with high potency.

Looking forward, the IL-17 market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into HS and other dermatologic conditions. The emergence of advanced biologics like sonelokimab and izokibep could shift market dynamics, offering more targeted, tissue-penetrant therapies that may outperform first-generation IL-17 inhibitors.

IL-17 Drugs Uptake

This section focuses on the uptake rate of potential emerging IL-17 expected to be launched in the market during 2025-2034.

IL-17 Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.

The presence of numerous drugs under different stages is expected to generate immense opportunity for IL-17 inhibitor market growth over the forecasted period.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for IL-17 inhibitor therapies.

KOL Views

To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on IL-17 Inhibitor's evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.

DelveInsight's analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as University of California, Yale University / Central Connecticut Dermatology, Kyoto University, University of Manchester / Salford Royal NHS Trust, CHU de Nantes, University of Lubeck, University of Verona, Hospital de la Santa Creu i Sant Pau, Barcelona, and others.

Their opinion helps understand and validate current and emerging therapy treatment patterns or IL-17 market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Key Updates on IL-17 Inhibitors

• In March 2025, UCB announced further long-term data from the Phase III trials and their open-label extensions, investigating BIMZELX in adults with moderate-to-severe plaque psoriasis, were presented as six posters at the 2025 American Academy of Dermatology (AAD) annual meeting in Orlando, Florida. Dual inhibition with bimekizumab-bkzx demonstrated high efficacy and sustained clinical benefits across different adult patient populations living with this common inflammatory skin condition.
• In March 2025, SFA Therapeutics announced the presentation of two head-to-head preclinical studies of its oral psoriasis treatment candidate, SFA-002, at the American Academy of Dermatology Annual Meeting in Orlando, Florida.
• In March 2025, SFA Therapeutics announced positive data from its Phase Ib clinical trial of SFA-002, an oral treatment for mild-to-moderate chronic plaque psoriasis. The study met its primary endpoint of safety, with no TRAEs or toxicities observed during the treatment period, and no rebound effects were noted.

List is not exhaustive, will be provided in the final report

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of the IL-17, explaining its mechanism, and therapies.
• Comprehensive insight into the Competitive Landscape, and forecasts, the future growth potential of treatment rate, drug uptake, and drug information have been provided.
• Additionally, an all-inclusive account of emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current landscape.
• A detailed review of the IL-17 market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis, expert insights/KOL views, and treatment preferences that help shape and drive the 7MM IL-17 market.

IL-17 Inhibitor Report Insights

• IL-17 Targeted Patient Pool
• Therapeutic Approaches
• IL-17 Pipeline Analysis
• IL-17 Market Size and Trends
• Existing and Future Market Opportunity

IL-17 Inhibitor Report Key Strengths

• Ten years Forecast
• The 7MM Coverage
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

IL-17 Inhibitor Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint)

Key Questions:

• What was the IL-17 inhibitor total market size, the market size by therapies, market share (%) distribution, and what would it look like in 2034? What are the contributing factors for this growth?
• Which drug is going to be the largest contributor in 2034?
• Which is the most lucrative market for IL-17 Inhibitor?
• What are the risks, burdens, and unmet needs of treatment with IL-17 -based/targeting therapies? What will be the growth opportunities across the 7MM for the patient population of IL-17 -based/targeting therapies?
• What are the key factors hampering the growth of the IL-17 Inhibitor market?
• What are the indications for which recent novel therapies and technologies have been developed to overcome the limitations of existing treatments?
• What key designations have been granted to the therapies for IL-17 inhibitors?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred therapy options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to buy:

• The report will help develop business strategies by understanding the latest trends and changing dynamics driving the IL-17 Inhibitor Market.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of indication-wise current and emerging therapies under the conjoint analysis section to provide visibility around leading indications.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Interleukin-17 (IL-17) Inhibitors

4. Key Events

5. Epidemiology and Market Forecast Methodology of IL-17 Inhibitors

6. IL-17 Inhibitors Market Overview at a Glance in the 7MM

• 6.1. Market Share (%) Distribution by Therapies in 2024
• 6.2. Market Share (%) Distribution by Therapies in 2034
• 6.3. Market Share (%) Distribution by Indications in 2024
• 6.4. Market Share (%) Distribution by Indications in 2034

7. IL-17 Inhibitors: Background and Overview

• 7.1. Introduction
• 7.2. Potential of IL-17 Inhibitor in Different Indications
• 7.3. Clinical Applications of IL-17 Inhibitor

8. Target Patient Pool

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: 7MM
• 8.3. Epidemiology Scenario in the 7MM
• 8.4. Total Cases in Selected Indications for IL-17 Inhibitors in the 7MM
• 8.5. Total Eligible Patient Pool for IL-17 Inhibitors in Selected Indications in the 7MM
• 8.6. Total Treated Cases in Selected Indications for IL-17 Inhibitors in the 7MM

9. Marketed Products of IL-17 Inhibitors

• 9.1. Key Competitors
• 9.2. BIMZELX (bimekizumab): UCB Pharma
  • 9.2.1 . Product Description
  • 9.2.2 . Regulatory Milestones
  • 9.2.3 . Other Developmental Activities
  • 9.2.4 . Clinical Development
    • 9.2.4.1. Clinical Trial Information
  • 9.2.5 . Safety and Efficacy
  • 9.2.6. Analyst Views
• 9.3. SILIQ/KYNTHEUM/LUMICEF (brodalumab): AstraZeneca/Bausch Health/Kyowa Kirin/LEO Pharma
  • 9.3.1 . Product Description
  • 9.3.2 . Regulatory Milestones
  • 9.3.3 . Other Developmental Activities
  • 9.3.4 . Clinical Development
    • 9.3.4.1. Clinical Trial Information
  • 9.3.5 . Safety and Efficacy
  • 9.3.6. Analyst Views

10. Emerging Therapies of IL-17 Inhibitors

• 10.1. Key Competitors
• 10.2. Sonelokimab: MoonLake Immunotherapeutics
  • 10.2.1 . Product Description
  • 10.2.2. Other Developmental Activities
  • 10.2.3 . Clinical Development
    • 10.2.3.1. Clinical Trial Information
  • 10.2.4 . Safety and Efficacy
  • 10.2.5. Analyst Views
• 10.3. Izokibep: Affibody Medical AB
  • 10.3.1 . Product Description
  • 10.3.2. Other Developmental Activities
  • 10.3.3 . Clinical Development
    • 10.3.3.1. Clinical Trial Information
  • 10.3.4 . Safety and Efficacy
  • 10.3.5. Analyst Views

11. IL-17 Inhibitor: Seven Major Market Analysis

• 11.1. Key Findings
• 11.2. Market Outlook of IL-17 Inhibitor
• 11.3. Conjoint Analysis of IL-17 Inhibitor
• 11.4. Key Market Forecast Assumptions of IL-17 Inhibitor
  • 11.4.1. Cost Assumptions and Rebates
  • 11.4.2. Pricing Trends
  • 11.4.3. Analogue Assessment
  • 11.4.4. Launch Year and Therapy Uptakes
• 11.5. Total Market Size of IL-17 Inhibitor in the 7MM
• 11.6. Market Size of IL-17 Inhibitor by Indication in the7MM
• 11.7. The United States Market Size
  • 11.7.1. Market Size of IL-17 Inhibitor by Indication in the United States
  • 11.7.2. Market Size of IL-17 Inhibitor by Therapies in the United States
• 11.8. EU4 and the UK Market Size
  • 11.8.1. Market Size of IL-17 Inhibitor by Indication in EU4 and the UK
  • 11.8.2. Market Size of IL-17 Inhibitor by Therapies in EU4 and the UK
• 11.9. Japan Market Size
  • 11.9.1. Market Size of IL-17 Inhibitor by Indication in Japan
  • 11.9.2. Market Size of IL-17 Inhibitor by Therapies in Japan

12. Market Access and Reimbursement of IL-17 Inhibitors

13. SWOT Analysis of IL-17 Inhibitors

14. KOL Views of IL-17 Inhibitors

15. Unmet Needs of IL-17 Inhibitors

16. Appendix

• 16.1. Bibliography
• 16.2. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight